Urology Associated Group

Urología-01

2025 DATA

Gender perspective

Summary of activities

The Department of Urology conducts research aimed at improving the diagnosis, treatment and follow-up of both oncological and benign urological diseases. Its research activities integrate clinical trials, translational studies and innovation projects in surgery, pharmacology, medical devices and regenerative medicine. The group actively participates in studies designed to evaluate new therapeutic approaches, assess the efficacy and safety of surgical techniques, and explore tools that support the transition towards more precise, personalised and patient-centred medicine. In this context, the group is promoting several projects based on artificial intelligence to enhance clinical data analysis, optimise diagnostic processes, support therapeutic decision-making, and develop predictive models capable of anticipating the course of specific urological diseases. These activities facilitate the translation of scientific knowledge into clinical practice and contribute to the development of innovative solutions for highly prevalent and impactful urogenital disorders.

Contributions to society

Our research activity aims to translate scientific innovation into improved healthcare. Through clinical and translational research projects, we contribute to the development of new treatments, drugs, surgical techniques, diagnostic strategies and artificial intelligence-based digital tools, supporting a safer, more precise, more efficient and more personalised approach to medicine.

Moreover, part of our work is focused on improving the patient experience throughout the entire care pathway. We are involved in initiatives aimed at enhancing patient well-being, quality of life and support for individuals with urological diseases, incorporating technologies that facilitate follow-up, outcome prediction and shared decision-making.

The Department of Urology also participates in national and international collaborative networks, promoting knowledge exchange, the generation of scientific evidence and technology transfer for the benefit of patients and society.

Collaborations

The Department of Urology maintains an active network of collaborations with scientific societies, cooperative groups, foundations, hospital departments and academic institutions. These partnerships enable the development of multicentre studies, the promotion of new research lines and the advancement of knowledge in the field of genitourinary disorders.

The Department currently collaborates with a range of organisations and institutions, including:

• Spanish Association of Urology: Our research group is aligned with the objectives of the Spanish Association of Urology, which promotes multicentre research through its Multicentre Research Studies Platform. We participate in collaborative studies aimed at consolidating clinical data, evaluating treatments, developing national registries and improving patients' quality of life.
• Advanced Therapies Group of IIS-FJD: We collaborate in the development of innovative therapies for urinary incontinence through a regenerative medicine project based on mesenchymal stem cells.
• Foundation for research in Urology: We participate in a clinical study evaluating the treatment of high-risk non-muscle-invasive bladder tumours with IMUNO BCG Moreau RJ.
• European Uro-Oncology Group: We collaborate in a Phase II clinical trial on upper urinary tract urothelial carcinoma.
• UNICANCER, Health Cooperative Group: We participate in the ALBAN clinical trial, which evaluates the efficacy of atezolizumab in combination with BCG in patients with high-risk non-muscle-invasive bladder cancer.

In addition, the Department of Urology collaborates closely with the Departments of Oncology and Nephrology at Fundación Jiménez Díaz University Hospital (HUFJD) through the donation of biological samples for strategic research projects, including the TITANIA Study, focused on cancer diagnosis and therapies using multi-omics analysis, and the FJD-ENBIBA (European Nephrectomy Biobank) project.

PhD Theses

Urología-03

List of publications ordered by publication date

Current Evidence on Safety, Efficacy and Efficiency of Sublingual Vaccine Uromune® in Prevention of Recurrent Urinary Tract Infections: A Literature Review.

Hernández-Sánchez JE, Lorenzo-Gómez MF, González-Enguita C.

Pathogens. 2025 Dec 30.15(1).

PMID: 41599026

FI: 3,3

http://dx.doi.org/10.3390/pathogens15010042

Profile of patients practicing clean intermittent catheterization and associated resource consumption. Multicenter study in Spain.

Muller-Arteaga C, Resel Folkersma L, Medina-Polo J, López García-Moreno AM, González López R, García Sánchez C, Madurga Patuel B, Zubiaur Libano C, Blasco Hernández P, en representación del Grupo Registro de Cateterismo Limpio Intermitente en España (CILREG) (AEU-PIEM/2017/001).

Actas Urol Esp (Engl Ed). 2025.49(6):501756.

PMID: 40268085

FI: 1,2

http://dx.doi.org/10.1016/j.acuroe.2025.501756

Treatment of Pelvic Organ Prolapse by Robotic Sacrocolpopexy: Long-Term Outcomes.

Carracedo Calvo D, Toledo Jiménez M, Jerez Izquierdo T, Grañén García-Ibarrola C, Esteban Labrador L, Sánchez Encinas M.

Int Urogynecol J. 2025 Nov 22.

PMID: 41273377

FI: 1,8

http://dx.doi.org/10.1007/s00192-025-06440-3

The mesh fixation dilemma in robotic sacrocolpopexy: Absorbable or non-absorbable sutures? Insights from a high-volume observational cohort.

Carracedo D, Moscatiello P, Hernández I, Jerez T, Grañen C, Toledo M, Sanchez-Encinas MA.

Actas Urol Esp (Engl Ed). 2025 Nov.49(9):501866.

PMID: 41077246

FI: 1,2

http://dx.doi.org/10.1016/j.acuroe.2025.501866

Defining statistical cure in patients with T1 high-grade non-muscle-invasive bladder carcinoma treated with BCG immunotherapy.

Subiela JD, de la Parra I, Taborda J, Medina AA, Pichler R, Krajewski W, Ojeda CM, Mardomingo AF, Durán PDO, Pérez EL, González-Padilla DA, Aumatell J, Mori K, Scilipoti P, Longoni M, de Angelis M, Caño-Velasco J, Puentedura AL, Pujol LP, Contieri R, Gallioli A, Tukiendorf A, D'Andrea D, Teoh JY, Afferi L, Del Giudice F, Marcq G, Albisinni S, Soria F, Mertens LS, Laukhtina E, Tully K, Mari A, Guerrero-Ramos F, Alvarez-Maestro M, Martín CC, Melendres FA, Buisan O, López-González JA, Dominguez-Escrig JL, Aranda J, Elena JLR, Basile G, Santos VGD, Moschini M, Pradere B, Acosta EA, Palacio FL, Puig AC, Gajate P, Saiz A, Gontero P, Revilla FJB, From Young Academic Urologist: Urothelial Carcinoma Working Group.

BJU Int. 2025 Aug 29.

PMID: 40883258

FI: 4,5

http://dx.doi.org/10.1111/bju.16913

Advances in Label-Free Detection of Non-Muscle Invasive Bladder Cancer: A Critical Review.

Vera G, Cerda-Infante J, Fernández MI, Sánchez-Encinas M, Rojas PA.

Bioengineering (Basel). 2025 Aug 12.12(8).

PMID: 40868379

FI: 3,7

http://dx.doi.org/10.3390/bioengineering12080866

Targeted Antibiotic Prophylaxis in Percutaneous Nephrolithotomy: Results of a Protocol Based on Preoperative Urine Culture and Risk Assessment.

Osorio-Ospina F, Bueno-Serrano G, Alcoba-García MP, Tabares-Jiménez J, Gómez-Jordana-Mañas B, García-Criado E, Ruiz-de-Castroviejo J, Pérez-Aizpurua X, Tufet-I-Jaumot JJ, González-Páez R, Matta-Pérez JC, Yanes-Glaentzlin B, Jiménez-Abad JF, Alcázar Peral JM, Carrasco Antón N, Petkova-Saiz E, González-Enguita C.

J Clin Med. 2025 Jul 24.14(15).

PMID: 40806870

FI: 2,9

http://dx.doi.org/10.3390/jcm14155249

Impact of 3D Reconstruction and Printing on Surgical Outcomes in Renal Tumour Surgery.

Campos-Valverde D, Muñoz-Rodríguez JR, Fernández PC, Sánchez DL, Serrano GB, Arroyo FJD, Pérez-Utrilla M, Cadavid SP, Murillo DG, Torres AG, Acevedo DH, Valencia MC, García MPA, Isla AL, Puerto AP, Enguita CG, Calvo FJR.

Arch Esp Urol. 2025 Jun.78(5):534-540.

PMID: 40641162

FI: 0,9

http://dx.doi.org/10.56434/j.arch.esp.urol.20257805.72

Do patients with intermediate-risk renal carcinoma who receive adjuvant pembrolizumab really benefit in recurrence-free survival? Analysis of a cohort of nephrectomies over 10 years.

Rojas PA, Carracedo D, Moscatiello P, González L, Gimbernat H, Santiago M, Toledo M, Pereira N, Sánchez-Encinas M.

World J Urol. 2025 May 16.43(1):307.

PMID: 40377723

FI: 2,9

http://dx.doi.org/10.1007/s00345-025-05599-0

Shared Decision-making in Functional Urology: A Dream or Reality?

Hernández PB, Enguita CG, Martínez AM.

Eur Urol Focus. 2025 Apr 26.

PMID: 40287294

FI: 5,6

http://dx.doi.org/10.1016/j.euf.2025.04.023

New insights and emerging approaches in bladder-sparing treatment for muscle-invasive bladder cancer.

Subiela JD, Guerrero-Ramos F, Rodríguez-Faba Ó, Aumatell J, Gajate P, López-Campos F, Sevillano E, Hernández-Arroyo M, García-Rojo E, Artiles Medina A, Sáenz-Calzada D, Gómez-Cañizo C, Romero-Otero J, Couñago F.

Actas Urol Esp (Engl Ed). 2025 Apr 19:501758.

PMID: 40258413

FI: 1,2

http://dx.doi.org/10.1016/j.acuroe.2025.501758

Robotic augmentation enterocystoplasty as a treatment for overactive bladder syndrome: Case report.

Calvo DC, Jiménez MT, Moscatiello P, Izquierdo TJ, Rodríguez NP, Encinas MS.

Int J Surg Case Rep. 2025 Apr.129:111173.

PMID: 40117833

FI: 0,7

http://dx.doi.org/10.1016/j.ijscr.2025.111173

Evaluation and Analysis of Costs Associated with Prophylaxis of Recurrent Urinary Tract Infections (RUTIs) in Women.

Hernández-Sánchez JE, Szczesnieski JJ, Padilla-Fernández BY, González-Enguita C, Flores-Fraile J, Lorenzo-Gómez MF.

Microorganisms. 2025 Feb 11.13(2).

PMID: 40005759

FI: 4,2

http://dx.doi.org/10.3390/microorganisms13020393

Multicenter study of the impact of Urolift® implantation in patients undergoing medical treatment for lower urinary tract symptoms secondary to benign prostatic hyperplasia.

González Enguita C, López Martín L, Herranz Fernández LM, Sinues Ojas B, Barrera Rodríguez C, Extramiana Cameno J, Campá Bortoló J, Oscá García JM, Perán Teruel M, Gimeno Argente V, Navarro Beltrán A, López Alcina E, Povo Martín I, Salvador Pallás Costa Y, Budía Alba A, Ortiz Salvador J, Salgado Plonski JJ, Suárez Sal P, Fernández Arjona M.

Actas Urol Esp (Engl Ed). 2025 Feb 11:501708.

PMID: 39947294

FI: 1,2

http://dx.doi.org/10.1016/j.acuroe.2025.501708